



## **Flumequine**

Catalog No: tcsc2747



## **Available Sizes**

Size: 10mg

Size: 50mg



## **Specifications**

CAS No:

42835-25-6

Formula:

 $C_{14}H_{12}FNO_3$ 

**Pathway:** 

Cell Cycle/DNA Damage; Anti-infection

**Target:** 

Topoisomerase;Bacterial

**Purity / Grade:** 

>98%

**Solubility:** 

DMSO: 7.69 mg/mL (29.44 mM; Need ultrasonic)

**Alternative Names:** 

R-802

**Observed Molecular Weight:** 

261.25

## **Product Description**

Flumequine is a quinolone antibiotic, and acts as a **topoisomerase II** inhibitor, with an  $IC_{50}$  of 15  $\mu$ M (3.92  $\mu$ g/mL).



IC50 & Target: IC50: 15 μM (Topoisomerase II)<sup>[1]</sup>

In Vitro: Flumequine is a topoisomerase II inhibitor, with an IC $_{50}$  of 3.92 µg/mL, and less potently inhibits Gyrase, with an IC $_{50}$  of 1764 µg/mL. Flumequine (0-625 µg/mL) increases migration of nuclear DNA from CHL cells<sup>[1]</sup>. Flumequine inhibits Spanish field isolates of *B. hyodysenteriae* with MIC $_{50}$  and MIC $_{90}$  of 50 and 100 µg/mL, and MBC $_{50}$  and MBC $_{90}$  of 50, 200 µg/mL, respectively<sup>[2]</sup>. Flumequine suppresses *A. salmonicida* isolates with MIC ranging from 0.06 to 32 µg/mL<sup>[3]</sup>.

*In Vivo:* Flumequine (0-500 mg/kg, p.o.) causes dose-related DNA damage in the stomach, colon, and urinary bladder of mice, 1 and 3 h but not 24 h after its administration<sup>[1]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!